The PSA test cannot differentiate between aggressive and benign prostate disease and leads to overdiagnosis and unnecessary biopsies2, and these issues led the U. S. Preventive Services Task Force to recommend against PSA-based screening for prostate cancer. Here, KLK3 is linked to prostate carcinoma.